Company Name: |
Shanghai Hongye Biotechnology Co. Ltd
|
Tel: |
400-9205774 |
Email: |
sales@glpbio.cn |
Products Intro: |
Product Name:Vandetanib-d6 CAS:1174683-49-8 Purity:>98% Package:1mg;10mg;50mg;100mg;
|
Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
Tel: |
18818260767 |
Email: |
sales@chemegen.com |
Products Intro: |
Product Name:Vandetanib-d6 CAS:1174683-49-8 Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
Company Name: |
Shanghai isotope chemical co.,ltd
|
Tel: |
021-021-51600108 13062666369 |
Email: |
sales@chinaisotope.com |
Products Intro: |
Product Name:Vandetanib-d6 CAS:1174683-49-8 Purity:1mg Package:1mg Remarks:RMCV00023-1mg
|
Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
Tel: |
021-65675885 18964387627 |
Email: |
customer_service@efebio.com |
Products Intro: |
Product Name:Vandetanib-d6 CAS:1174683-49-8 Purity:98% (CP) Package:500μg;1mg;5mg
|
Company Name: |
Cayman Chemical Company
|
Tel: |
(800) 364-9897 |
Email: |
cayman@caymanchem.com |
Products Intro: |
Product Name:Vandetanib-d6 CAS:1174683-49-8
|
|
| Vandetanib-d6 Basic information |
Product Name: | Vandetanib-d6 | Synonyms: | Vandetanib-d6;N-(4-bromo-2-fluorophenyl)-6-(methoxy-d3)-7-[[1-(methyl-d3)-4-piperidinyl]methoxy]-4-quinazolinamine | CAS: | 1174683-49-8 | MF: | C22H24BrFN4O2 | MW: | 475.36 | EINECS: | | Product Categories: | | Mol File: | 1174683-49-8.mol | ![Vandetanib-d6 Structure](CAS/20211123/GIF/1174683-49-8.gif) |
| Vandetanib-d6 Chemical Properties |
storage temp. | Store at -20°C | solubility | DMSO: soluble; Methanol: soluble; THF: soluble | form | A solid |
| Vandetanib-d6 Usage And Synthesis |
Description | Vandetanib-d6 is intended for use as an internal standard for the quantification of vandetanib by GC- or LC-MS. Vandetanib is a multi-kinase inhibitor that inhibits VEGFR2, VEGFR3, VEGFR1, EGFR, PDGFRβ, Tie-2, and FGFR1 in cell-free assays (IC50s = 40, 110, 1,600, 500, 1,100, 2,500, and 3,600 nM, respectively).1,2 It also binds to 142 additional kinases in a panel of 442 kinases (Kds = 4.6-7,900 nM). Vandetanib (1 and 2.5 μM) induces apoptosis and cell cycle arrest at the G0/G1 phase in GEO colon and OVCAR-3 ovarian cancer cells.3 It inhibits proliferation of HAK1-B, KYN-2, and Huh7 hepatocarcinoma cells, as well as human umbilical vein endothelial cells (HUVECs), with IC50 values of 10, 8.1, 9.4, and 7.1 μM, respectively.4 Vandetanib (200 mg/kg) increases survival and decreases tumor angiogenesis and VEGFR2 levels in a D54MG glioblastoma mouse xenograft model.5 It reduces tumor growth in a variety of mouse xenograft models, including lung, colon, and breast cancer models, when administered at doses of 25, 50, and 100 mg/kg per day.1 Formulations containing vandetanib have been used in the treatment of medullary thyroid cancer. | References | 1. Wedge, S.R., Ogilvie, D.J., Dukes, M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res. 62(16),4645-4655(2002). 2. Davis, M.I., Hunt, J.P., Herrgard, S., et al. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29(11),1046-1051(2011). 3. Ciardiello, F., Caputo, R., Damiano, V., et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase Clin. Cancer Res. 9(4),1546-1556(2003). 4. Inoue, K., Torimura, T., Nakamura, T., et al. Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice Clin. Cancer Res. 18(14),3924-3933(2012). 5. Rich, J.N., Sathornsumetee, S., Keir, S.T., et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors Clin. Cancer Res. 11(22),8145-8157(2005). |
| Vandetanib-d6 Preparation Products And Raw materials |
|